{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:39:32Z","timestamp":1790631572028,"version":"4.1.0"},"reference-count":12,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2025,10,31]]},"DOI":"10.5582\/ddt.2025.01109","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T22:06:48Z","timestamp":1761689208000},"page":"358-359","source":"Crossref","is-referenced-by-count":5,"title":["Paltusotine: The first selective nonpeptide agonist of somatostatin receptor 2 (SSTR2) for the treatment of acromegaly"],"prefix":"10.5582","volume":"19","author":[{"given":"Yueyi","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoran","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R. Acromegaly. Nat Rev Dis Primers. 2019; 5:20.","DOI":"10.1038\/s41572-019-0071-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly: An update. Mayo Clin Proc. 2022; 97:333-346.","DOI":"10.1016\/j.mayocp.2021.11.007"},{"key":"3","unstructured":"3. Giustina A, Barkan A, Beckers A, <i>et al<\/i>. A consensus on the diagnosis and treatment of acromegaly comorbidities: An update. J Clin Endocrinol Metab. 2020; 105:dgz096."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Giustina A, Barkhoudarian G, Beckers A, <i>et al<\/i>. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020; 21:667-678.","DOI":"10.1007\/s11154-020-09588-z"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021; 24:1-13.","DOI":"10.1007\/s11102-020-01091-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Starnoni D, Daniel RT, Marino L, Pitteloud N, Levivier M, Messerer M. Surgical treatment of acromegaly according to the 2010 remission criteria: Systematic review and meta-analysis. Acta Neurochir (Wien). 2016 ; 158:2109-2121.","DOI":"10.1007\/s00701-016-2903-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018; 14:552-561.","DOI":"10.1038\/s41574-018-0058-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Liu S, Mathias SD, Gelbaum D, Shi L. Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord. 2020; 20:117.","DOI":"10.1186\/s12902-020-00595-4"},{"key":"9","unstructured":"9. FDA approves new treatment for acromegaly, a rare endocrine disorder. <i>https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-treatment-acromegaly-rare-endocrine-disorder<\/i> (Accessed October 4, 2025)."},{"key":"10","unstructured":"10. Crinetics Announces FDA Approval of PALSONIFY\u2122 (paltusotine) for the Treatment of Acromegaly in Adults. <i>https:\/\/crinetics.com\/crinetics-announces-fda-approval-of-palsonify-paltusotine-for-the-treatment-of-acromegaly-in-adults<\/i> (Accessed October 4, 2025)."},{"key":"11","unstructured":"11. PALSONIFY (paltusotine) tablets, for oral use. <i>https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219070s000lbl.pdf<\/i> (Accessed October 4, 2025)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Melmed S, di Filippo L, Fleseriu M, <i>et al<\/i>. Consensus on acromegaly therapeutic outcomes: An update. Nat Rev Endocrinol. 2025; 21:718-737.","DOI":"10.1038\/s41574-025-01148-2"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/5\/19_2025.01109\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T04:12:04Z","timestamp":1763179924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/5\/19_2025.01109\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2025.01109","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"2025.01109"}}